BRIEF—Mitsubishi's ALS therapy approved in Canada

The first new therapy for amyotrophic lateral sclerosis (ALS) in a generation, Radicava (edaravone), has won approval in Canada.

The intravenous therapy, a free-radical scavenger thought to protect motor neurons from oxidative stress, was developed by Japanese drugmaker Mitsubishi Tanabe Pharma.

It was first approved in Japan, and  was also approved in the USA last year. The firm’s European regulatory submission is still under consideration.